ImmutepSTU:YP1A -3.78%23 Quick Ratio is 2.97 as of Dec. 2025, which is 75% below its 10-year median of 11.94. GuruFocus rates STU:YP1A with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Immutep ranks worse than 55.96% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Immutep's quick ratio for the quarter that ended in Dec. 2025 was 2.97.
Immutep has a quick ratio of 2.97. It generally indicates good short-term financial strength.
The historical rank and industry rank for Immutep's Quick Ratio or its related term are showing as below:
STU:YP1A'
s Quick Ratio Range Over the Past 10 Years
Min: 2.97 Med: 11.94 Max: 18.86
Current: 2.97
During the past 13 years, Immutep's highest Quick Ratio was 18.86. The lowest was 2.97. And the median was 11.94.
STU:YP1A's Quick Ratio is ranked worse than 55.96% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs STU:YP1A: 2.97
Immutep (STU:YP1A) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Immutep Quick Ratio Related Terms
Immutep Quick Ratio Historical Data
* Premium members only.
The historical data trend for Immutep's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:YP1A vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Immutep's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immutep Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immutep's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Immutep's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Immutep's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immutep (STU:YP1A) has a Quick Ratio of 2.97 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Immutep and its competitors. This is 75% below median its historical median of 11.94. Over the past decade, Immutep's Quick Ratio has ranged from 2.97 to 18.86. According to the industry distribution chart, Immutep ranks #789 out of 1410 companies in the Biotechnology industry, placing it in the top 56%.
Is Immutep's Quick Ratio too high?
Immutep's current Quick Ratio of 2.97 is 75% below median its 10-year median of 11.94. Over the past 10 years, this metric has ranged from a low of 2.97 to a high of 18.86. The Biotechnology industry median Quick Ratio is 3.60. Immutep's value of 2.97 is 17.5% below this industry median. Based on the distribution chart, Immutep ranks #789 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immutep has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Immutep's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immutep ranks #789 out of 1410 companies for Quick Ratio. This places Immutep in the lower half of its industry. The industry median Quick Ratio is 3.60. Immutep's value of 2.97 is 17.5% below this benchmark. Historically, Immutep's own Quick Ratio has ranged from 2.97 to 18.86 over the past decade. While the company's 10-year median is 11.94 vs. the industry median of 3.60, Immutep has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immutep's current Quick Ratio of 2.97 is 17.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Immutep and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immutep's current Quick Ratio is 2.97, which is 75% below median its own 10-year median of 11.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (STU:YP1A) has a current Quick Ratio of 2.97. The current Quick Ratio is 2.97, which is 75% below median its 10-year median of 11.94 and 17.5% below the Biotechnology industry median of 3.60. Immutep's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Immutep (STU:YP1A), the current Quick Ratio is 2.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
23GF Score
Get the complete analysis for STU:YP1A
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:YP1A has been successfully added to your 
